| Name | Title | Contact Details |
|---|---|---|
Nolan Berlew |
Chief Information Security Officer | Profile |
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
Stiefel, a GSK Company is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Watson Laboratories is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harendorf Technolgy is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
REM Associates is a Bonsall, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.